Development of Green Mei Products for the Prevention of Metabolic Syndrome

Last updated: September 2, 2021
Sponsor: Chung Shan Medical University
Overall Status: Completed

Phase

N/A

Condition

Diabetes Prevention

Williams Syndrome

Stress

Treatment

N/A

Clinical Study ID

NCT05039437
CS2-19033
  • Ages 20-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The aim of this study is to investigate the antihypertensive effects of Mei-Gin formula-4 (MGF-4) and Mei-Gin formula-7.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • The age of the subject is 20 to 70 years old.
  • The subject is a patient with hypertension (SBP is between 130-179 mmHg, DBP isbetween 85-109mmHg, one of the two can be diagnosed), and there are no seriousillnesses requiring hospitalization during the study period treatment.
  • No hypertension medication.
  • The subject can understand the test process described in the consent form and thepossible potential risks and benefits, and able to sign the consent form.
  • The subjects shall observe diet control during the trial period.

Exclusion

Exclusion Criteria:

  • Subjects diagnosed with cancer and still under active treatment.
  • Subjects diagnosed with heart disease and still under active treatment.
  • Other drugs are used, whose pharmacological effects may affect blood pressure or mayaggravate the effects of drugs.
  • Subjects who have systemic infection and need systemic antibiotics.

Study Design

Total Participants: 50
Study Start date:
June 15, 2019
Estimated Completion Date:
December 31, 2019

Study Description

It's a randomized, and single-blind trial and was designed to evaluate the effects of MGFs (MGF-4 and MGF-4) on blood pressure. 50 participants with hypertension (systolic blood pressure between 130-179 mmHg or diastolic blood pressure between 85-109 mmHg) who did not accept any hypertension medication were randomized allocated to either MGF-4 or MGF-7 group. Participants were instructed to take 4 capsules of MGF-4 or MGF-7 daily throughout the duration of the 8 weeks intervention study. After treatment, the change of the blood pressure and relative mechanism were analyzed.

Connect with a study center

  • Chung Shan Medical University

    Taichung, South 402
    Taiwan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.